Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Uber Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Uber Technologies Inc trades at $78.31 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 5.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Uber Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UBER | |
|---|---|---|
Market Cap | $29.03B | $159.38B |
Sector | Health | Industrials |
52-Week High | $491.22 | $100.10 |
52-Week Low | $205.48 | $65.94 |
Enterprise Value | $26.99B | $168.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.
Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.
Uber (UBER) trades at $78.54, up 4.69% today, reflecting strong bullish momentum. The stock shows robust fundamentals with revenue growth from $44.0B in 2024 to $52.0B in 2025 and a net income margin of 19.32%. Technical indicators are bullish, with the price above key support levels and moving averages signaling upward trend. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Spain and Germany, though cost management is evident through HR layoffs and AI spending caps.
The outlook for Uber is positive, driven by revenue expansion and profitability improvements, but risks include intense competition and regulatory scrutiny. Analyst consensus is strongly bullish with a $102.88 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
